JP Morgan Upgrades Corteva to Overweight, Lowers Price Target to $19

JP Morgan analyst Jeffrey Zekauskas has upgraded Corteva (NYSE: CTVA) from Neutral to Overweight. However, the price target has been significantly lowered from $83 to $19.